Video

Dr. Chughtai highlights recent advances in diagnostics for male LUTS

"When it comes to BPH therapy, we've seen a lot of innovation when it comes to the therapeutics; the diagnostics have been a tiny bit behind," says Bilal Chughtai, MD.

In this interview, Bilal Chughtai, MD, highlights takeways from his discussion, “Advances in Diagnostics in Male LUTS,” which was presented during the 2023 American Urological Association Annual meeting in Chicago, Illinois. Chughtai is an associate professor of urology at Weill Cornell Medical College in New York City, NY.

Video Transcript:

So, when it comes to the advances in diagnostics, I think we're seeing a lot of great innovation in that space altogether. When it comes to BPH therapy, we've seen a lot of innovation when it comes to the therapeutics; the diagnostics have been a tiny bit behind. I think this year, we're seeing innovation like sound-based apps to calculate UroFlow, voided volume, [to] understand bladder health. We're seeing that with also CarePath. CarePath is a comprehensive technology that tracks home uroflows, but also gives patients tidbits of information to help them understand where they are in the treatment algorithm and also how they can better their care and who needs to move on to minimally invasive therapies and potentially even surgical therapies. Lastly, we're also seeing innovation in urodynamics as well, where when you think about classical urodynamics, their patients are tethered by multiple cords as well as catheters. With BrightUro we're starting to see innovation with a completely seamless system where the patient is not tethered by anything. And ultimately, they would have the bladder filled and then they would empty their bladder to understand how the bladder filling cycle works and what the underlying bladder condition is.

This transcription has been edited for clarity.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Daniel Carson, MD, MS, answers a question during a Zoom video interview
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Related Content
© 2024 MJH Life Sciences

All rights reserved.